VYNE logo

VYNE THERAPEUTICS INC

VYNENASDAQ
πŸ† #4557 by market capUS Equity
$25.14β–² $24.63 (+4839.10%)
Market closed Β· at close
πŸ””
Track VYNE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 4839.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ–Ό 13.3%
1yβ–² 39.8%
🏦Market Cap
$17M
Small Cap
πŸ“ˆRevenue Growth (YoY)
13.8%
Healthy
πŸ“ŠGross Margin
99.2%
High
πŸ’΅FCF Margin
-12696.4%
Thin
βš–οΈP/S Ratio
24.3x
Expensive
Otter Score
56
Fair

Trading Snapshot

Day Range
$24.94 – $25.19
52-Week Range
β€”
Volume (shares)
2,419
Avg Volume (shares)
β€”
Shares Outstanding
667,700
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$570,000
Last Q Revenue
β€”
P/E Ratio
-0.0
P/S Ratio
24.3x
EPS (TTM)
$-197.53
Dividend Yield
70.45%
Dilution (1yr)
+0.4%
VYNE logo

VYNE THERAPEUTICS INC

VYNE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$570Kβ–² +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%β–Ό βˆ’4.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$30Mβ–Ό βˆ’31.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$33Mβ–Ό βˆ’2.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
855Kβ–² +0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24Mβ–² +$4M YoY
StockOtter Β· stockotter.space

About VYNE THERAPEUTICS INC

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
56/100
Analyst data unavailable.

Latest News & Updates

News unavailable.